Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial;Langzeitwirkung von Dapagliflozin bei Typ-2-Diabetikern unter hoch dosierter Insulintherapie: Eine randomisierte, kontrollierte Studie

Deutsche Medizinische Wochenschrift

Volumn 138, Issue SUPPL. 1, 2013, Pages

  Wilding, J P H ^a   Woo, V ^b   Soler, N G ^c   Pahor, A ^d   Sugg, J ^d   Rohwedder, K ^d   Parikh, S ^d  

^a Forschungsgruppe Diabetes und Endokrinologie   (United Kingdom)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Springfield Zentrum für Diabetes und Endokrinologie   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

dapagliflozin; SGLT 2 inhibitors; type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO;

ADD ON THERAPY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY TRACT INFECTION;

AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LONG-TERM CARE; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84875286392     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1305284     Document Type: Article

References (30)

1. Hoerger T. J., Segel J. E., Gregg E. W. et al. Is glycemic control improving in U.S. adults? Diabetes Care: 2008; 31 81 86
2. Hsu W. C. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J: 2009; 102 67 76
3. Buse J. Combining insulin and oral agents. Am J Med: 2000; 108 06 23S 32S
4. Holman R. R., Thorne K. I., Farmer A. J. et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med: 2007; 357 1716 1730 (Pubitemid 350005153)
5. Nathan D. M., Buse J. B., Davidson M. B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care: 2009; 32 193 203
6. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet: 1998; 352 837 853
7. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care: 2001; 24 758 767 (Pubitemid 32888861)
8. Holman R. R., Farmer A. J., Davies M. J. et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med: 2009; 361 1736 1747
9. Wright E. M., Hirayama B. A., Loo D. F. Active sugar transport in health and disease. J Intern Med: 2007; 261 32 43 (Pubitemid 46046470)
10. Han S., Hagan D. L., Taylor J. R. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes: 2008; 57 1723 1729
11. Meng W., Ellsworth B. A., Nirschl A. A. et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem: 2008; 51 1145 1149 (Pubitemid 351480378)
12. Komoroski B., Vachharajani N., Boulton D. et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther: 2009; 85 520 526
13. Ferrannini E., Jimenez Ramos S., Salsali A. et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care: 2010; 33 2217 2224
14. Komoroski B., Vachharajani N., Feng Y. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther: 2009; 85 513 519
15. List J. F., Woo V., Morales E. et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care: 2009; 32 650 657
16. Bailey C. J., Gross J. L., Pieters A. et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet: 2010; 375 2223 2233
17. Strojek K., Yoon K., Hruba V. et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab: 2011; 13 928 938
18. Wilding J. P., Norwood P., T'Joen C. et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care: 2009; 32 1656 1662
19. Verbeke G., Molenberghs G. Linear Mixed Models for Longitudinal Data. New York Springer-Verlag: 2000
20. Ratitch B., O'Kelly M. Implementation of Pattern-Mixture Models Using Standard SAS/STAT Procedures (PharmaSUG2011 - Paper SP04). 2011; http://www.quintiles.com/elements/media/inthenews/implementation-pattern- mixture-models-using-standard-sasstat-procedures.pdf (Stand: 20.07.2011)
21. Zhang M., Tsiatis A. A., Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics: 2008; 64 707 715
22. Pi-Sunyer F. X. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med: 2009; 121 94 107
23. Charbonnel B., DeFronzo R., Davidson J. et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metabolism: 2010; 95 2163 2171
24. Hermansen K., Kipnes M., Luo E. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab: 2007; 9 733 745 (Pubitemid 47261855)
25. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon: 2003; 49 53 70 (Pubitemid 36350775)
26. Shah B. R., Hux J. E. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care: 2003; 26 510 513 (Pubitemid 36929083)
27. Bohannon N. J. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care: 1998; 21 451 456 (Pubitemid 28101084)
28. Vigneri P., Frasca F., Sciacca L. et al. Diabetes and cancer. Endocrine-related cancer: 2009; 16 1103 1123
29. Larsson S. C., Orsini N., Brismar K. et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia: 2006; 49 2819 2823 (Pubitemid 44730282)
30. Bristol Myers-Squibb, AstraZeneca US Food & Drug Administration Endocrinologic & Metabolic Advisory Committee background document: dapagliflozin, BMS-512148, NDA 202293. US Food and Drug Administration www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262993.htm (Stand: 26.09.2011)